Lipigon Pharmaceuticals AB

OSTO:LPGO (Sweden)  
kr 0.35 (+20.41%) May 17
At Loss
P/B:
1.57
Market Cap:
kr 44.75M ($ 4.18M)
Enterprise V:
kr 12.83M ($ 1.20M)
Volume:
1.41M
Avg Vol (2M):
435.14K
Also Trade In:
Volume:
1.41M
At Loss
Avg Vol (2M):
435.14K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Lipigon Pharmaceuticals AB ( OSTO:LPGO ) from 2021 to May 20 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Lipigon Pharmaceuticals AB stock (OSTO:LPGO) PE ratio as of May 20 2024 is 0. More Details

Lipigon Pharmaceuticals AB (OSTO:LPGO) PE Ratio (TTM) Chart

To

Lipigon Pharmaceuticals AB (OSTO:LPGO) PE Ratio (TTM) Historical Data

Total 827
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 10
Lipigon Pharmaceuticals AB PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-05-20 At Loss 2024-03-12 At Loss
2024-05-17 At Loss 2024-03-11 At Loss
2024-05-16 At Loss 2024-03-08 At Loss
2024-05-15 At Loss 2024-03-07 At Loss
2024-05-14 At Loss 2024-03-06 At Loss
2024-05-13 At Loss 2024-03-05 At Loss
2024-05-10 At Loss 2024-03-04 At Loss
2024-05-08 At Loss 2024-03-01 At Loss
2024-05-07 At Loss 2024-02-29 At Loss
2024-05-06 At Loss 2024-02-28 At Loss
2024-05-03 At Loss 2024-02-27 At Loss
2024-05-02 At Loss 2024-02-26 At Loss
2024-04-30 At Loss 2024-02-23 At Loss
2024-04-29 At Loss 2024-02-22 At Loss
2024-04-26 At Loss 2024-02-21 At Loss
2024-04-25 At Loss 2024-02-20 At Loss
2024-04-24 At Loss 2024-02-19 At Loss
2024-04-23 At Loss 2024-02-16 At Loss
2024-04-22 At Loss 2024-02-15 At Loss
2024-04-19 At Loss 2024-02-14 At Loss
2024-04-18 At Loss 2024-02-13 At Loss
2024-04-17 At Loss 2024-02-12 At Loss
2024-04-16 At Loss 2024-02-09 At Loss
2024-04-15 At Loss 2024-02-08 At Loss
2024-04-12 At Loss 2024-02-07 At Loss
2024-04-11 At Loss 2024-02-06 At Loss
2024-04-10 At Loss 2024-02-05 At Loss
2024-04-09 At Loss 2024-02-02 At Loss
2024-04-08 At Loss 2024-02-01 At Loss
2024-04-05 At Loss 2024-01-31 At Loss
2024-04-04 At Loss 2024-01-30 At Loss
2024-04-03 At Loss 2024-01-29 At Loss
2024-04-02 At Loss 2024-01-26 At Loss
2024-03-28 At Loss 2024-01-25 At Loss
2024-03-27 At Loss 2024-01-24 At Loss
2024-03-26 At Loss 2024-01-23 At Loss
2024-03-25 At Loss 2024-01-22 At Loss
2024-03-22 At Loss 2024-01-19 At Loss
2024-03-21 At Loss 2024-01-18 At Loss
2024-03-20 At Loss 2024-01-17 At Loss
2024-03-19 At Loss 2024-01-16 At Loss
2024-03-18 At Loss 2024-01-15 At Loss
2024-03-15 At Loss 2024-01-12 At Loss
2024-03-14 At Loss 2024-01-11 At Loss
2024-03-13 At Loss 2024-01-10 At Loss

Lipigon Pharmaceuticals AB (OSTO:LPGO) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Lipigon Pharmaceuticals AB develops medicines for diseases caused by disorders of the body's handling of fats. It focuses on orphan drugs for unusual diseases where there is no adequate treatment.